TWi Biotechnology, Inc.

TWi Biotechnology, Inc. is a clinical-stage biopharmaceutical company based in Taipei, Taiwan, that develops and sells drugs for innate immunity-related diseases. Its pipeline includes AC-203, in Phase 2 clinical trials for indications such as epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes mellitus; AC-1101, in Phase Ib trials for vitiligo and in preclinical stage for atopic dermatitis, granuloma annulare, and rare autoimmune skin diseases; and NORA520, an oral prodrug that is hydrolyzed to Brexanolone. The company has a drug development agreement with Hong Kong Winhealth Pharma Group Co., Limited for the Mainland China, Hong Kong, and Macao markets. Founded in 2010, TWi Biotechnology operates as a subsidiary of Xinchen Investment Company.